17 research outputs found
«Green economy» as a component to achieve stability of the state
У статті розглянуто сутність економічної категорії «зелена економіка». Проаналізовано глобальні проблеми людства, що призвели до виникнення концепції «зеленої економіки». Досліджено місце України серед інших держав світу в екологічному та економічному аспектах. Обґрунтовано вагомість впровадження «зеленої економіки» у провідні галузі господарства. Виявлено стратегічні пріоритети розвитку «зеленої економіки» в Україні. Запропоновано інноваційні напрями розвитку держави в контексті «зеленої економіки» задля забезпечення сталого розвитку суспільства у майбутньому.The article describes the essence of economic category of «green economy». Analyzed global problems of humanity, which led to the emergence of the concept of «green economics». Studied Ukraine’s place among the other nations of the world in environmental and economic aspects. Grounded importance in the implementation of green economics major industries. There are given the strategic priorities of the «green economy» in Ukraine. Offer innovative directions of development of the state in the context of the «green economy» for the sustainable development of society in the future
Guidelines to individual tasks on discipline «Economic theory» for full-time students and distance learning training directions: 6.030502 «Economic Cybernetics», 6.030503 «International Economics», 6.030507 «Marketing»
Методичні вказівки підготовлені відповідно до кредитно-модульної системи в організації навчального процесу.Methodical instructions are prepared according to credit-modular system to the organization of educational process
Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis
Новий мінеральний препарат для ветеринарної практики «Кальфомін»
A new pharmaceutical composition “Calfоmin”, that includes macro-and trace elements in the form of water-soluble salts, namely Calcium, Phosphorus, Magnesium, Natrium, Potassium, Ferum, Mangan, Zinc, Cobalt and Kuprom, is presented in the article. Also drug include essential amino acids - methionine and lysine. The drug is used for the treatment and prevention of diseases of cows, pigs, sheep and goats, associated with metabolic disorders of the listed nutrients (postpartum paresis, rachitis in young animals, osteomalacia in the elderly animals). The drug is effective in allergies, toxicosis, postpartum hemoglobinuria, spotted disease, hives, exanthema, hemorrhagic diathesis, hematuria and myoglobinuria; paresis due to a deficit of Calcium or Phosphorus of different etiology. “Calfоmin» is recommended as an auxiliary therapy for Poisoning with Lead, Fluorine or Acidic Acid, and for poultry to improve egg-laying. The drug is used to increase the weight gain of animals on fattening, etc.
When administered to laboratory animals in the stomach, intraperitoneally and subcutaneously, it is established that the drug belongs to the IV class toxicity according to the GCM 85.2-37-736: 2011 and GOST 12.1.007-76, that is, it belongs to low-toxic substances. The data on the significant increase in Calcium, inorganic Phosphorus, Zinc and Kuprum in the serum of domesticated cows, which were orally called “Calfоmin”, were obtained on the 3rd day. And on the 14th day the activity of these elements was already within the limits of physiological norms. Oral administration to cows “Calfоmin” in a dose of 30 ml per 100 kg of body weight for 10 days after a calving prevents postpartum paresis. “Calfоmin” is of interest to veterinary medicine, and therefore it is expedient to continue its further clinical study and standardize the indicators of its quality.У статті представлено нову фармацевтичну композицію «Кальфомін», що включає макро- та мікроелементи у вигляді водорозчинних солей, а саме: Кальцій, Фосфор, Магній, Натрій, Калій, Ферум, Манган, Цинк, Кобальт та Купрум. Також до складу препарату входять незамінні амінокислоти – метіонін та лізин. Препарат застосовують для лікування та профілактики захворювань корів, свиней, овець і кіз, пов’язаних з порушенням метаболізму перерахованих нутрієнтів (післяродового парезу, рахіту у молодих тварин, остеомаляції у старих тварин). Лікарський засіб ефективний при алергіях, токсикозах, післяродовій гемоглобінурії, плямистій хворобі, кропив’янці, екзантемі, геморагічному діатезі, гематурії і міоглобінурії; парезі внаслідок дефіциту Кальцію або Фосфору різної етіології. Рекомендовано “Кальфомін” в якості допоміжної терапії при отруєннях Свинцем, Фтором або Щавлевою кислотою, а для птиці для покращення яйценосності. Препарат застосовують для збільшення приросту живої ваги тварин на відгодівлі, тощо.
При введенні лабораторним тваринам у шлунок, внутрішньоочеревно і підшкірно, встановлено, що препарат належить до IV класу токсичності згідно СОУ 85.2-37-736:2011 та ГОСТ 12.1.007-76, тобто відноситься до малотоксичних речовин. Отримано дані про суттєве підвищення уже на 3-тю добу загального Кальцію, неорганічного Фосфору, Цинку та Купруму у сироватці крові отелених корів, яким перорально задавали “Кальфомін”. А на 14-ту добу активність цих елементів уже була в межах фізіологічних норм. Пероральне введення коровам “Кальфоміну” в дозі 30 мл на 100 кг маси тіла протягом 10 діб після отелу запобігає післяродовому парезу. “Кальфомін” представляє інтерес для ветеринарної медицини і тому доцільно продовжити його подальше клінічне дослідження і стандартизувати показники його якості
NEXUS Arch: A Multicenter Study Evaluating the Initial Experience With a Novel Aortic Arch Stent Graft System
Objective: To assess the initial clinical experience with a novel endograft system (NEXUS Aortic Arch Stent Graft System) designed to treat aortic arch pathologies and address the morphology and hemodynamic challenges of the aortic arch. Summary background data: The aortic arch remains the most challenging part of the aorta for both open and endovascular repair. Transcatheter aortic arch repair has the potential to significantly reduce surgical risks. Methods: Patients underwent transcatheter aortic arch repair with a single branch, 2 stent graft system, implanted over a through-and-through guidewire from the brachiocephalic trunk, to the descending aorta with an ascending aorta stent graft. The ascending aorta stent graft is deployed into a designated docking sleeve to connect the 2 stent grafts and isolate the aortic arch pathology. Proximal landing zone in all cases was in Zone 0. Anatomical inclusion criteria included adequate landing zone in the ascending aorta, brachiocephalic trunk, and descending thoracic aorta. Preparatory debranching procedure was performed in all patients with carotid-carotid crossover bypass and left carotid to left subclavian bypass, or parallel graft from descending aorta to left subclavian artery. Safety and performance were evaluated through 1 year. Survival analysis used the Kaplan-Meier method. Results: Twenty-eight patients, 79% males, with a mean age of 72.2 ± 6.2 years were treated with 100% procedural success. Isolated aortic arch aneurysm was the principle pathology in 17 (60.7%) of patients, while chronic aortic dissection was the principle pathology in 6 (21.4%) of patients. The remaining 5 (17.8%) had combined or other pathologies. At 1 month, the vascular pathology was excluded in 25 of 26 alive patients (96.1%). The 30 days mortality rate was 7.1%, stroke rate was 3.6% (all nondisabling), and combined mortality/stroke rate was 10.7%. One-year mortality was 10.7%, without device or aneurysm-related death. Two patients (7.1%) reported stroke or transient ischemic attack at 1 year that recovered completely. One year combined mortality/stroke rate was 17.8%. There were 3 patients (10.7%) that had device-related unplanned reinterventions through 1 year. Conclusions: The NEXUS Aortic Arch Stent Graft System, a novel single branch, 2 stent graft system used for endovascular aortic arch repair that requires landing in the ascending aorta, demonstrates a high success rate with excellent 1 year safety and performance
A multicentre trial of patient specific rehearsal prior to EVAR:Impact on Procedural Planning and Team Performance
\u3cp\u3eObjective Patient specific rehearsal (PsR) prior to endovascular aneurysm repair (EVAR) enables the endovascular team to practice and evaluate the procedure prior to treating the real patient. This multicentre trial aimed to evaluate the utility of PsR prior to EVAR as a pre-operative planning and briefing tool. Material and methods Patients with an aneurysm suitable for EVAR were randomised to pre-operative or post-operative PsR. Before and after the PsR, the lead implanter completed a questionnaire to identify any deviation from the initial treatment plan. All team members completed a questionnaire evaluating realism, technical issues, and human factor aspects pertinent to PsR. Technical and human factor skills, and technical and clinical success rates were compared between the randomised groups. Results 100 patients were enrolled between September 2012 and June 2014. The plan to visualise proximal and distal landing zones was adapted in 27/50 (54%) and 38/50 (76%) cases, respectively. The choice of the main body, contralateral limb, or iliac extensions was adjusted in 8/50 (16%), 17/50 (34%), and 14/50 (28%) cases, respectively. At least one of the abovementioned parameters was changed in 44/50 (88%) cases. For 100 EVAR cases, 199 subjective questionnaires post-PsR were completed. PsR was considered to be useful for selecting the optimal C-arm angulation (median 4, IQR 4-5) and was recognised as a helpful tool for team preparation (median 4, IQR 4-4), to improve communication (median 4, IQR 3-4), and encourage confidence (median 4, IQR 3-4). Technical and human factor skills and technical and initial clinical success rates were similar between the randomisation groups. Conclusion PsR prior to EVAR has a significant impact on the treatment plan and may be useful as a pre-operative planning and briefing tool. Subjective ratings indicate that this technology may facilitate planning of optimal C-arm angulation and improve non-technical skills. Trial registration: URL://www.clinicaltrials.gov. Unique identifier: NCT01632631.\u3c/p\u3